TISIDB

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF12796 Ankyrin repeats (3 copies) PF15808 BCL-6 co-repressor PF16553 BCORL-PCGF1-binding domain
Function	Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells; the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2).

> Gene Ontology [ TOP ]
Biological Process	GO:0000414 regulation of histone H3-K36 methylation GO:0000415 negative regulation of histone H3-K36 methylation GO:0001503 ossification GO:0006479 protein methylation GO:0006513 protein monoubiquitination GO:0007389 pattern specification process GO:0007507 heart development GO:0008213 protein alkylation GO:0009798 axis specification GO:0010390 histone monoubiquitination GO:0010452 histone H3-K36 methylation GO:0016570 histone modification GO:0016571 histone methylation GO:0016574 histone ubiquitination GO:0018022 peptidyl-lysine methylation GO:0018205 peptidyl-lysine modification GO:0030278 regulation of ossification GO:0030279 negative regulation of ossification GO:0030282 bone mineralization GO:0030500 regulation of bone mineralization GO:0030502 negative regulation of bone mineralization GO:0031056 regulation of histone modification GO:0031057 negative regulation of histone modification GO:0031060 regulation of histone methylation GO:0031061 negative regulation of histone methylation GO:0031214 biomineral tissue development GO:0032259 methylation GO:0033522 histone H2A ubiquitination GO:0034505 tooth mineralization GO:0034968 histone lysine methylation GO:0035518 histone H2A monoubiquitination GO:0042476 odontogenesis GO:0042481 regulation of odontogenesis GO:0042483 negative regulation of odontogenesis GO:0043414 macromolecule methylation GO:0051568 histone H3-K4 methylation GO:0051569 regulation of histone H3-K4 methylation GO:0051572 negative regulation of histone H3-K4 methylation GO:0060021 palate development GO:0065001 specification of axis polarity GO:0070167 regulation of biomineral tissue development GO:0070168 negative regulation of biomineral tissue development GO:0070170 regulation of tooth mineralization GO:0070171 negative regulation of tooth mineralization GO:1902275 regulation of chromatin organization GO:1905268 negative regulation of chromatin organization GO:2000027 regulation of organ morphogenesis
Molecular Function	GO:0003714 transcription corepressor activity GO:0004842 ubiquitin-protein transferase activity GO:0008134 transcription factor binding GO:0019787 ubiquitin-like protein transferase activity GO:0031072 heat shock protein binding GO:0042826 histone deacetylase binding
Cellular Component	GO:0031519 PcG protein complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between BCOR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between BCOR and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27505670	Diffuse Large B Cell Lymphoma	Inhibit immunity	Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific binding by the BCL6 transcriptional repressor and the presence of a non-canonical PRC1-BCOR-CBX8 complex. The chromodomain protein CBX8 is induced in GC B cells, binds to H3K27me3 at bivalent promoters, and is required for stable association of the complex and the resulting histone modifications. Moreover, oncogenic BCL6 and EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial targeting of these repressors results in enhanced anti-lymphoma activity in DLBCLs.

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of BCOR in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of BCOR in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.112	0.598
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.38	0.784
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.086	0.935
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.498	0.149
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.41	0.85
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.609	0.824
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.284	0.388
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.214	0.888
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.376	0.823
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.81	0.513
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.175	0.517
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.046	0.498

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of BCOR in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	0	9.5	0.492
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	7.4	-2.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	7.7	1.4	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	7.1	-7.1	0.467
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BCOR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BCOR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BCOR. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BCOR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of BCOR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between BCOR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	BCOR
Name	BCL6 corepressor
Aliases	FLJ20285; KIAA1575; BCL6 co-repressor; ANOP2; MAA2; MCOPS2; BCL-6 interacting corepressor; BCL-6 corepressor
Chromosomal Location	Xp11.4
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting BCOR collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse BCOR